Pay in 4 interest-free payments of $24.75 Learn more
Ships within 48 hours · Estimated delivery Jul 25 - Jul 30
It induces neuronal differentiation in human cortical neuronal cells (HCN)
and STAT-3
23)/b22-21+
Low doses of ACY-1215 combined with bortezomib triggered synergistic anti- multiple myeloma (anti-MM) activity
22)23/h4-7
GPR39-C3 - GPR39 Agonist. CAS# 1621175-65-2 size:2 mg solid It induces neuronal differentiation inGPR39 C3, CAS No. 1621175 65 2, is the first potent, selective and orally bioavailable GPR39 agonist with an EC50 ~0. 8 nM for human GPR39 and ~0. 4 nM for rodent GPR39. It has no inhibitory effects (at 10 M) on a panel of kinases and exhibits no relevant binding affinity for the related ghrelin and neurotensin 1 receptors and other enzymes, transporters, and GPCRs. GPR39 C3 has excellent functional activity in physiologically relevant rodent cells
US$ 169.00
US$ 117.00
US$ 604.50
US$ 178.00
US$ 162.00
US$ 112.00
US$ 295.00